AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT04426864 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Home-based Stretching Exercises Group
Description: Each exercise was described to the patient by visually. For each muscle group exercise was performed for 3-4 times and each repeat was 30 seconds long. The muscle groups which were involved in stretching exercises were upper trapezius, rhomboid, hip flexor, hamstring, pectoral, piriformis, quadriceps, gastrocnemius, soleus, levator scapulae, hip adductor and tensor fasciae late muscles. Exercise program was applied 3 days in a week during 12 weeks. Each participant was called every 2 weeks to maintain compliance.
Study NCT02677025 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Young Women's Health CoOp (YWHC)
Description: Participants in this group will participate in two workshops of the young woman-focused intervention about HIV/STIs (sexually transmitted infections), sexual behaviors, alcohol and other drug use, violence, communication skills, and other issues. Participants will develop personalized risk reduction action plans at the end of each workshop session.
Study NCT02677025 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: HIV Counseling/Testing
Description: Participants will be tested for HIV and if positive will receive counseling in accordance with national standards.
Study NCT00708435 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Beriplex® P/N (Kcentra)
Description: Intravenous infusion, dosage depending on baseline INR, amount of coagulation factor IX and body weight
Study NCT00708435 — intervention group
Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Fresh frozen plasma
Description: Intravenous Infusion, dosage depending on baseline INR and body weight
Study NCT03540875 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Closed loop anesthesia
Description: Propofol and Remifentanil are administered automatically using a closed-loop system.~The goal of this study is to compare manual titration versus automated titration of propofol and remifentanil in adult patients undergoing surgery guided by the electro-cortical activity. The aim in both group is to maintain the qCon in the range 40-60 during induction and maintenance of general anesthesia using the propofol in TCI mode. But also the qNox in the range 40-60 using remifentanil. The controller is based on a Proportional-Integral-derivative algorithm which steers a target to the pumps during induction and maintenance of general anesthesia.
Study NCT03540875 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: Propofol
Description: The dosage is modified automatically by the device or according to the new medical prescription.
Study NCT03540875 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Propofol
Description: The dosage is modified automatically by the device or according to the new medical prescription.
Study NCT03540875 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: Remifentanil
Description: The dosage is modified automatically by the device or according to the new medical prescription.
Study NCT03540875 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Remifentanil
Description: The dosage is modified automatically by the device or according to the new medical prescription.
Study NCT01210521 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Vitamin D
Description: Vitamin D, (2000IU) will be administered orally, once a day, for one month.
Study NCT02186587 — intervention group
Intervention type: DEVICE
Group type: OTHER
Intervention: ConforMIS custom total knee
Description: Total knee arthroplasty using ConforMIS custom total knee system with follow-up at 6 months
Study NCT01914471 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Students for Nutrition and eXercise
Description: These schools received the entirety of Students for Nutrition and eXercise, a middle-school-based obesity-prevention intervention combining school-wide environmental changes, multimedia, encouragement to eat healthy school cafeteria foods, and peer-led education and marketing
Study NCT04019613 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: Lung ultrasound
Description: Lung ultrasound will be performed at baseline (resting), prior to exercise with passive leg elevation, after 1.5 minutes of 20 Watts exercise, during each subsequent stage, at peak workload and at 1 minute recovery. Pulmonary thermodilution will be performed at rest, peak stress and at 1 minute recovery.
Study NCT02241083 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Dopamine
Study NCT02241083 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Norepinephrine
Study NCT02241083 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: no medication
Study NCT01167738 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: capecitabine
Description: 1250 mg/mq days 1-28 every 4 weeks
Study NCT01167738 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: capecitabine
Description: 1250 mg/mq days 1-28 every 4 weeks
Study NCT01167738 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: cisplatin
Description: 30 mg/mq on days 1 and 15 every 4 weeks
Study NCT01167738 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: cisplatin
Description: 30 mg/mq on days 1 and 15 every 4 weeks
Study NCT01167738 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: epirubicin
Description: 30 mg/mq on days 1 and 15 every 4 weeks
Study NCT01167738 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: epirubicin
Description: 30 mg/mq on days 1 and 15 every 4 weeks
Study NCT01167738 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: gemcitabine
Description: 800 mg/mq on days 1 and 15 every 4 weeks
Study NCT01167738 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: gemcitabine
Description: 800 mg/mq on days 1 and 15 every 4 weeks
Study NCT01167738 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: metformin
Description: 2 g days 1-28 every 4 weeks
Study NCT01298869 — intervention group
Intervention type: BIOLOGICAL
Intervention: HPV-6/11/16/18 vaccine
Description: HPV-6/11/16/18 vaccination 3 doses at day 1, month 2, and month 6
Study NCT04644926 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Remote ischemic conditioning
Description: Remote ischemic conditioning (RIC) procedure comprise three repetitions of brachial cuff inflation to 200 mmHg for five minutes following deflation to 0 mmHg for another five minutes. The procedure overall took 30 minutes.
Study NCT03933618 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: Anastrozole 1mg
Study NCT03933618 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: Clomiphene Citrate 25mg
Study NCT03933618 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: Placebo - Cap
Study NCT02952092 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: roxadustat
Description: Oral
Study NCT02952092 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Darbepoetin alfa
Description: Intravenous
Study NCT02415699 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Fluorouracil
Study NCT02415699 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fluorouracil
Study NCT02415699 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Oxaliplatin
Study NCT02415699 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Oxaliplatin
Study NCT02415699 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Leucovorin
Study NCT02415699 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Leucovorin
Study NCT02415699 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: DC-CIK
Study NCT02028559 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Propulse 1
Description: Move kidney stones with Propulse 1 device.
Study NCT01896284 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 0.5mg aflibercept
Description: 0.5mg aflibercept intravitreal injection will be performed every 4 weeks from baseline to week 8 (3 doses) and every 8 weeks until week 32.
Study NCT03042962 — intervention group
Intervention type: OTHER
Intervention: MRI
Description: Functional and structural MRI of the brain will be conducted to identify disorder specific neural markers
Study NCT03042962 — intervention group
Intervention type: PROCEDURE
Intervention: Blood draw
Description: Blood samples will be collected, the DNA will be extracted and banked for genetic studies
Study NCT01673763 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Stent insertion into the main pancreatic duct
Description: Stent insertion into the main pancreatic duct
Study NCT02565719 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: REP 2139-Mg
Description: REP 2139-Mg = magnesium chelate complex of REP 2139
Study NCT02565719 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: REP 2139-Mg
Description: REP 2139-Mg = magnesium chelate complex of REP 2139
Study NCT02565719 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pegasys
Description: immunotherapy
Study NCT02565719 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Pegasys
Description: immunotherapy
Study NCT02565719 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Viread
Description: HBV RT polymerase inhibitor
Study NCT02565719 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Viread
Description: HBV RT polymerase inhibitor
Study NCT02565719 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: REP 2165-Mg
Description: REP 2165-Mg = magnesium chelate complex of REP 2165
Study NCT02565719 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: REP 2165-Mg
Description: REP 2165-Mg = magnesium chelate complex of REP 2165
Study NCT03337932 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Doxycycline 100 milligram Oral Tablet bid, 7 days
Description: Patients will receive doxycycline for 7 days.
Study NCT03337932 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Doxycycline 100 milligram Oral Tablet bid, 14 days
Description: Patients will receive doxycycline for 14 days.
Study NCT03337932 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Controls without a history of lyme disease.
Description: No intervention.
Study NCT02788630 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Sleep hygiene counseling
Description: The mothers of the eligible infants will be visited at home and will be invited to participate at the study. To those who sign the Consent Form (CF) a following visit will be scheduled to within 5 days. Between CF signature and the 5-day visit, the enrolled children will use an actigraph-device in the leg and the mothers will fill out a sleep diary registering the times of the day the child is asleep, awake, napping, and feeding. At the 5-day visit the child allocation in the trial (intervention or control group) will be uncovered and the sleep recommendations will be delivered to mothers in the intervention group. Phone calls on days 6 and 7 and a home visit on day 8 will be paid to support mothers for possible difficulties in implementing the recommendations.
Study NCT02621346 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Imagery
Description: Prior to exercising participants will be given an imagery script. Afterwards, participants will imagine completing the leg press.
Study NCT02621346 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Muscle Maintenance
Description: Participants complete the leg press exercises at an intensity that promotes muscle maintenance but not muscle growth
Study NCT02621346 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Bicep Curls
Description: Control group participants will complete a bicep exercise at a maintenance training intensity.
Study NCT04085302 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Digital Behaviour Change Intervention
Description: 14 days
Study NCT00382824 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Coenzyme Q10
Description: active drug
Study NCT00382824 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo
Study NCT01691521 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Mepolizumab IV
Description: Mepolizumab 75 mg IV will be administered every 4 weeks with the last dose at Week 28
Study NCT01691521 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Mepolizumab SC
Description: Mepolizumab 100 mg SC will be administered every 4 weeks with the last dose at Week 28
Study NCT01691521 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: IV Placebo
Description: Normal saline (placebo) will be administered IV every 4 weeks with the last dose at Week 28
Study NCT01691521 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: IV Placebo
Description: Normal saline (placebo) will be administered IV every 4 weeks with the last dose at Week 28
Study NCT01691521 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SC Placebo
Description: Normal saline (placebo) will be administered SC every 4 weeks with the last dose at Week 28
Study NCT01691521 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: SC Placebo
Description: Normal saline (placebo) will be administered SC every 4 weeks with the last dose at Week 28
Study NCT01402843 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: pitavastatin, valsartan, placebo
Description: pitavastatin 4mg/day 8 week valsartan 320mg/day 8 week
Study NCT01402843 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: pitavastatin, valsartan, placebo
Description: pitavastatin 4mg/day 8 week valsartan 320mg/day 8 week
Study NCT03380078 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Teams Leadership Institute (TLI)
Description: TLI is training for leaders in how to improve implementation of evidence-based interventions in community settings. TLI includes 5 key components : 1. Assessment: The Implementation Leadership Scale (ILS) and Implementation Climate Scale (ICS) will be completed by first-level leaders participating in the intervention, his/her subordinates (i.e. providers) and executive leaders. 2. Initial Training: a 3-hour didactic and interactive session that includes training in implementation leadership Leaders will develop a plan for using specific implementation support strategies. 3. Coaching: Weekly, brief (15-30 min) coaching calls keep leaders on track with goals and plans. Coaching includes review of progress toward goals, updating plan based on emergent issues, and problem solving. 4. Follow up : At month 4, leaders attend a 2-hour booster session . 5. Graduation: TLI programs will have a group-based graduation for the leaders and provider trainees at EBI training completion.
Study NCT00916461 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Minocycline
Description: Minocycline + treatment as usual. 50 mg twice daily increasing to 200 mgs per day, increments of 50 mgs every 2 weeks.
Study NCT00916461 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo + treatment as usual.
Study NCT00067119 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Aggrenox
Study NCT00067119 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Study NCT01241383 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bosentan
Description: Bosentan 62.5mg bid x 4 weeks; up-titrated to 125mg bid x 20 weeks
Study NCT02712125 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: isosorbide mononitrate
Description: 20 mg isosorbide mononitrate (IMN) tablet applied vaginally once daily until delivery .
Study NCT02712125 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: placebo vaginal tablets once daily until delivery
Study NCT00357721 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Atazanavir Sulphate
Description: Capsules, Oral, 200 mg, twice daily, 7 days.
Study NCT03380078 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Motivational Enhancement (TIPS for Training)
Description: The TIPS module applies MI principles and strategies to address attitudinal barriers and improve engagement in training. I AIM HI and CPRT trainers (in the TIPS Conditions ) will incorporate MI during training and ongoing consultation/coaching with providers to increase provider engagement and problem solving throughout training: 1. Providers will receive a call designed to provide information about training and the intervention. 2. During the workshop, trainers will assess concerns about participating and will use reflective problem solving to address barriers . Trainers will work with the provider to develop a plan through the use of Planning Worksheets . 3. During each consultation , planning worksheets will be updated collaboratively with the provider. 4. Providers will receive a weekly motivational text to encourage on-going participation.
Study NCT03380078 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Classroom Pivotal Response Teaching (CPRT)
Description: CPRT is a naturalistic behavioral intervention adapted from pivotal response training (PRT) for use during classroom activities to target social, communication, behavior, and learning skills. CPRT is a manualized program with user-friendly materials for training, intervention planning and fidelity monitoring provided in printed and web-based formats. CPRT has an established training plan and the training curriculum that follows the manual. Training and coaching including standard EBI training is conducted by MA or postdoctoral level researchers with extensive training and experience with CPRT.
Study NCT03380078 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Classroom Pivotal Response Teaching (CPRT)
Description: CPRT is a naturalistic behavioral intervention adapted from pivotal response training (PRT) for use during classroom activities to target social, communication, behavior, and learning skills. CPRT is a manualized program with user-friendly materials for training, intervention planning and fidelity monitoring provided in printed and web-based formats. CPRT has an established training plan and the training curriculum that follows the manual. Training and coaching including standard EBI training is conducted by MA or postdoctoral level researchers with extensive training and experience with CPRT.
Study NCT03380078 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: An Individualized Mental Health Intervention for ASD (AIM HI)
Description: A package of well-established, evidence-based behavioral strategies designed to reduce challenging behaviors in children served in MH service settings. AIM HI is a manualized program with user-friendly materials for training, intervention planning and fidelity monitoring provided in printed and web-based formats. AIM HI is a package of evidence-based parent-mediated and child focused strategies, designed to reduce behavior problems in children with ASD ages 5 to 13 served in MH programs. AIM HI has an established training plan and the training curriculum follows the manual. Training and coaching is conducted by MA or postdoctoral level researchers with extensive training and experience with AIM HI.
Study NCT03380078 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: An Individualized Mental Health Intervention for ASD (AIM HI)
Description: A package of well-established, evidence-based behavioral strategies designed to reduce challenging behaviors in children served in MH service settings. AIM HI is a manualized program with user-friendly materials for training, intervention planning and fidelity monitoring provided in printed and web-based formats. AIM HI is a package of evidence-based parent-mediated and child focused strategies, designed to reduce behavior problems in children with ASD ages 5 to 13 served in MH programs. AIM HI has an established training plan and the training curriculum follows the manual. Training and coaching is conducted by MA or postdoctoral level researchers with extensive training and experience with AIM HI.
Study NCT03380078 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Team-Enhanced Teams Leadership Institute (TLI)
Description: TLI-2 enhances TLI training by (a) including additional team members important to EBI implementation (e.g., supervisors, support staff) and (b) including the team in the development of an implementation plan using a team charter process. TLI-2 includes 5 components : 1. Assessment: The Implementation Climate Scale (ICS) will be completed by team members, providers, and executive leaders. 2. Initial Training: a 3-hour didactic and interactive session that includes training for the implementation team in implementation climate and development of an implementation plan. 3. Coaching: Bi-monthly, brief (15-30 min) coaching calls keep the team on track with goals and plans. Coaching includes review of progress toward goals, updating plan based on emergent issues, and problem solving. 4. Follow up: At month 4, team members attend a 2-hour booster session . 5. Graduation: TLI-2 programs will have a group-based graduation for the leaders and provider trainees at EBI training completion.
Study NCT00357721 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Atazanavir Sulphate
Description: Capsules, Oral, 300 mg, twice daily, 8 days.
Study NCT00357721 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Atazanavir Sulphate
Description: Capsules, Oral, 400 mg, twice daily, 9 days.
Study NCT04146246 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: G6PD assay
Description: A test for G6PD deficiency.